Pharmaceutical R&D does not always start with soup and end with nuts, although by analogy this is the classic route followed by what is now the large multinational sector of the industry. A shortcut version of the full programme is followed by generics companies and specialty pharma, who prefer to delay until the entrÃ©e is […]
There may be interesting cases…where the combination of a low-risk deuterated active can be combined with a new therapeutic use, and synergistically deliver a new product that is medically advantageous and significantly differentiated.
At the Society for Biomolecular Sciences meeting in Lille in April 2009, time was set aside for a symposium on drug repurposing. In addition to Numedicus, there were talks from Didier Leroy for the Medicines for Malaria Venture, and from Chris Lipinski, of Melior Discovery. Melior operate a two-part strategy, to provide screening services for […]